[go: up one dir, main page]

PE20221260A1 - Analogos de insulina novedosos y usos de estos - Google Patents

Analogos de insulina novedosos y usos de estos

Info

Publication number
PE20221260A1
PE20221260A1 PE2022000971A PE2022000971A PE20221260A1 PE 20221260 A1 PE20221260 A1 PE 20221260A1 PE 2022000971 A PE2022000971 A PE 2022000971A PE 2022000971 A PE2022000971 A PE 2022000971A PE 20221260 A1 PE20221260 A1 PE 20221260A1
Authority
PE
Peru
Prior art keywords
insulin analogs
desb30
novel insulin
analog
insulin analog
Prior art date
Application number
PE2022000971A
Other languages
English (en)
Inventor
Frantisek Hubalek
Mathias Norrman
Helle Birk Olsen
Peter Madsen
Thomas Børglum Kjeldsen
Jeppe Sturis
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PE20221260A1 publication Critical patent/PE20221260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un analogo de insulina humana de accion rapida que comprende las sustituciones de aminoacidos en las posiciones A9E, B3E, B26E, desB30; A9E, B3E, B27E, B28E, desB30; entre otros. Tambien se refiere a una composicion farmaceutica que comprende el analogo de insulina de la invencion en una concentracion de 0.6 mM a 3 mM, un compuesto nicotinico tal como la nicotinamida y se encuentra libre de zinc. Dicho analogo es util en el tratamiento o prevencion de afecciones medicas relacionadas con la diabetes.
PE2022000971A 2019-12-11 2020-12-10 Analogos de insulina novedosos y usos de estos PE20221260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11
PCT/EP2020/085541 WO2021116292A1 (en) 2019-12-11 2020-12-10 Novel insulin analogues and uses thereof

Publications (1)

Publication Number Publication Date
PE20221260A1 true PE20221260A1 (es) 2022-08-16

Family

ID=68886882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000971A PE20221260A1 (es) 2019-12-11 2020-12-10 Analogos de insulina novedosos y usos de estos

Country Status (29)

Country Link
US (3) US11498951B2 (es)
EP (2) EP4073097B1 (es)
JP (2) JP6995284B2 (es)
KR (1) KR102427426B1 (es)
CN (1) CN114787184A (es)
AR (1) AR120717A1 (es)
AU (1) AU2020402135A1 (es)
BR (1) BR112022009510A2 (es)
CA (1) CA3159114A1 (es)
CL (1) CL2023000086A1 (es)
CO (1) CO2022007273A2 (es)
DK (1) DK4073097T3 (es)
ES (1) ES2985989T3 (es)
FI (1) FI4073097T3 (es)
HR (1) HRP20241042T1 (es)
HU (1) HUE067827T2 (es)
IL (2) IL319162A (es)
LT (1) LT4073097T (es)
MA (1) MA58093B1 (es)
MX (2) MX2022006251A (es)
MY (1) MY208364A (es)
PE (1) PE20221260A1 (es)
PH (1) PH12022551094A1 (es)
PL (1) PL4073097T3 (es)
PT (1) PT4073097T (es)
RS (1) RS65822B1 (es)
SI (1) SI4073097T1 (es)
TW (1) TWI773009B (es)
WO (1) WO2021116292A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
PE20221260A1 (es) * 2019-12-11 2022-08-16 Novo Nordisk As Analogos de insulina novedosos y usos de estos
KR20230057686A (ko) 2021-10-22 2023-05-02 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
ATE317443T1 (de) 1996-12-20 2006-02-15 Novo Nordisk As N-terminal verlängerte proteine exprimiert in hefe
EP1005490B1 (en) 1997-03-20 2006-03-29 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
EP1039920A4 (en) 1997-10-24 2003-05-28 Lilly Co Eli INSULIN ANALOGS ACYLATED BY FATTY ACID
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
WO2007096431A1 (en) 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009022013A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
US9242011B2 (en) 2008-04-01 2016-01-26 Novo Nordisk A/S Insulin albumin conjugates
US20120184487A1 (en) 2009-06-30 2012-07-19 Novo Nordisk A/S Insulin derivatives
ES2552401T3 (es) 2009-11-02 2015-11-27 Novo Nordisk A/S Solución farmacéutica de albúmina unida no covalentemente e insulina acilada
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
WO2013086927A1 (zh) 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
PE20221260A1 (es) 2019-12-11 2022-08-16 Novo Nordisk As Analogos de insulina novedosos y usos de estos

Also Published As

Publication number Publication date
DK4073097T3 (da) 2024-08-19
MX2023000398A (es) 2023-02-02
IL292762B2 (en) 2025-10-01
EP4073097B1 (en) 2024-07-03
LT4073097T (lt) 2024-09-10
MX2022006251A (es) 2022-06-22
US20240141011A1 (en) 2024-05-02
SI4073097T1 (sl) 2024-09-30
PL4073097T3 (pl) 2024-10-28
HUE067827T2 (hu) 2024-11-28
ES2985989T3 (es) 2024-11-08
MA58093B1 (fr) 2024-09-30
FI4073097T3 (fi) 2024-08-13
IL319162A (en) 2025-04-01
CL2023000086A1 (es) 2023-08-04
PH12022551094A1 (en) 2024-06-24
TW202136289A (zh) 2021-10-01
KR102427426B1 (ko) 2022-08-01
BR112022009510A2 (pt) 2022-08-16
WO2021116292A1 (en) 2021-06-17
CO2022007273A2 (es) 2022-08-19
CA3159114A1 (en) 2021-06-17
JP2021119193A (ja) 2021-08-12
RS65822B1 (sr) 2024-09-30
IL292762B1 (en) 2025-06-01
PT4073097T (pt) 2024-08-16
AU2020402135A1 (en) 2022-06-02
US12122818B2 (en) 2024-10-22
AR120717A1 (es) 2022-03-09
US12152063B2 (en) 2024-11-26
EP4480492A2 (en) 2024-12-25
EP4073097A1 (en) 2022-10-19
US11498951B2 (en) 2022-11-15
HRP20241042T1 (hr) 2024-11-08
JP6995284B2 (ja) 2022-01-14
JP2021091685A (ja) 2021-06-17
US20210179685A1 (en) 2021-06-17
CN114787184A (zh) 2022-07-22
TWI773009B (zh) 2022-08-01
MY208364A (en) 2025-05-01
IL292762A (en) 2022-07-01
US20230192801A1 (en) 2023-06-22
EP4480492A3 (en) 2025-03-19
KR20210141748A (ko) 2021-11-23

Similar Documents

Publication Publication Date Title
PE20221260A1 (es) Analogos de insulina novedosos y usos de estos
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
PE20161408A1 (es) Composiciones de insulina de rapida accion
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
PE20220954A1 (es) Compuesto de 2,6-dioxo-3,6-dihidropirimidina, bactericida agricola y horticola, nematicida y agente antifungico medico y veterinario
PE20191205A1 (es) Composiciones farmaceuticas que contienen insulina
AR112353A1 (es) Compuesto de insulina acilada
MY184813A (en) Oral care compositions and methods of use
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
RU2016114098A (ru) Новое производное аналога инсулина
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
CL2020000310A1 (es) Análogos de insulina acilados novedosos y usos de estos.
JP2017502074A5 (es)
CL2025000632A1 (es) Compuestos de insulina acilada de acción temporal prolongada
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
MX2023013972A (es) Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
UY37490A (es) Análogos de insulina de acción rápida de estabilidad mejorada.
EP4317173A4 (en) PEPTIDE AND COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
UA109760C2 (uk) Біологічно активні пептидні комплекси
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
CU20200102A7 (es) Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas